IAG Cargo significantly boosts Tel Aviv route capacity
The carrier is replacing its remaining Airbus A321s with wide-body Boeing 777-200s, which will operate twice a day and promises to prove beneficial to Israel’s time and temperature-sensitive pharmaceuticals sector, which is currently in a growth phase.
Customers will now benefit from a daily lift of 29 tonnes; representing a net increase of 2500 tonnes in summer 2016 compared to the same time this year, which is an increase of 72 percent.
Alan Dorling, Global Head of Pharmaceuticals & Life Sciences at IAG Cargo, commented: “Tel Aviv is a thriving business centre and it’s also one of the most important regions for the manufacture of pharmaceuticals. Through the additional capacity delivered by the 777-200, we can now offer manufacturers in the region greater lift, helping them, as they look to grow their businesses.”
The additional capacity will be particularly beneficial to businesses operating within Tel Aviv’s high-growth pharmaceuticals sector. Israel is a major manufacturer of pharmaceutical products and its total pharmaceuticals market is expected to grow to $2.3 billion by 2020. Connecting through IAG Cargo’s London GDP approved Heathrow hub, Israeli drug companies’ benefit from access to 106 Constant Climate approved destinations, including extensive connections to the high-growth pharmaceuticals markets of Latin America.
IAG Cargo is the single business created following the merger of British Airways World Cargo and Iberia Cargo in April 2011. In 2014 the operations of British Airways World Cargo and Iberia Cargo had a commercial revenue of €992 million. It has a combined workforce of more than 2,400 people covering a global network of over 350 destinations.